ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

The combination of sacituzumab govitecan and pembrolizumab demonstrated a 44.4% clinical complete response rate in muscle-invasive bladder cancer patients. The 12-month event-free survival and ...

Pembrolizumab shows significant OS and DFS benefits in ccRCC, with a 72-month OS rate of 86.1% versus 79.4% for placebo. DFS benefits are more pronounced in subgroups with sarcomatoid features and ...

Padeliporfin VTP therapy shows high efficacy with an 86.5% overall response rate and 73% complete response rate in low-grade UTUC. The therapy provides an organ-sparing alternative to ...

Sasanlimab combined with BCG improved event-free survival in high-risk NMIBC patients, particularly those with CIS and T1 tumors. Subgroup analyses showed EFS benefits across different disease stages, ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

SYNC-T therapy SV-102 combines an in situ vaccine with intratumoral infusion, targeting mCRPC. The trial focuses on safety, tolerability, and efficacy. Phase 1 results showed an 87% overall response ...

“This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.

Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and ...